Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators

Fig. 2

Impact of CPA/6d treatment on LLC tumor microvessel density. Immunohistochemcal staining of blood vessel marker CD31 in LLC tumor sections from untreated or CPA/6d-treated tumors, 6 days after the third CPA treatment. a, relative CD31 staining intensity, mean ± SE for n = 8 tumors/group; *p < 0.05 by two-tailed t-test. b, representative figure for each tumor group shown in (a)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us